A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine

Table 4 Summary of efficacy data from observational studies and meta-analyses

Outcome, months	Lenvatinib	Sorafenib
Outcome, months	Range from observational studies	Range from observational studies	Estimate from meta-analysis by Thomas et al. 2014 [45]	Estimate from meta-analysis by Shen et al. 2014 [44]
OS, median	31.8–32.3 ^[2]	23–34.5 ^{[3] a}	- ^c	- ^c
PFS, median	12.6–25.8 ^[2]	12–22.1 ^{[4] b}	17.9	- ^c
95% CI			17.9–18 ^[7]
ORR, %	50–68 ^[2]	15–38.3 ^[7]	20.9	22
95% CI			14.3–27.5 ^[6]	15–28 ^[7]

- = not applicable, CI Confidence interval, ORR Objective tumour response rate, OS Overall survival, PFS Progression-free survival
^aAn additional study reported that the median OS had not been met [28]
^bOne other study reported that the median PFS had not been met [28] and another reported mean PFS only (9.7 months) [30]; in this latter study sorafenib was studied at half the dose of all other studies and included only 9 patients
^c No meta-analyses were identified
^[x] denotes the number of studies from which data are derived

ISSN: 1471-2407